BIOTON Valuation

Is BIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BIO (PLN3.14) is trading above our estimate of fair value (PLN0.76)

Significantly Below Fair Value: BIO is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIO?

Key metric: As BIO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BIO. This is calculated by dividing BIO's market cap by their current revenue.
What is BIO's PS Ratio?
PS Ratio	1.5x
Sales	zł177.60m
Market Cap	zł266.18m

BIO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.8x
Enterprise Value/EBITDA	38.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does BIO's PS Ratio compare to its peers?

The above table shows the PS ratio for BIO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	5.6x
SVE Synthaverse	4.9x	n/a	zł307.1m
MAB Mabion	1.8x	-10.4%	zł192.0m
CTX Captor Therapeutics Spolka Akcyjna	10.9x	30.2%	zł233.1m
RDG Read-Gene	4.7x	n/a	zł54.2m
BIO BIOTON	1.5x	n/a	zł266.2m

Price-To-Sales vs Peers: BIO is good value based on its Price-To-Sales Ratio (1.5x) compared to the peer average (5.6x).

Price to Sales Ratio vs Industry

How does BIO's PS Ratio compare vs other companies in the European Biotechs Industry?

38 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	8.0x	21.8%
BIO BIOTON	1.5x	n/a	US$63.92m

38 Companies		Estimated Growth	Market Cap
Industry Avg.	8.0x	43.0%
BIO BIOTON	1.5x	n/a	US$63.92m

No more companies

Price-To-Sales vs Industry: BIO is good value based on its Price-To-Sales Ratio (1.5x) compared to the European Biotechs industry average (8x).

Price to Sales Ratio vs Fair Ratio

What is BIO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BIO's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.